Disposition of 10846 shares by Booth Bruce of Kymera Therapeutics at 40.66 subject to Rule 16b-3
| KYMR Stock | USD 43.70 3.09 7.61% |
Slightly above 55% of Kymera Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Kymera Therapeutics suggests that some traders are interested. Kymera Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Kymera Therapeutics. Many technical investors use Kymera Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Kymera |
Filed transaction by Kymera Therapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Kymera Therapeutics Fundamental Analysis
We analyze Kymera Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kymera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kymera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Kymera Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kymera Therapeutics stock to make a market-neutral strategy. Peer analysis of Kymera Therapeutics could also be used in its relative valuation, which is a method of valuing Kymera Therapeutics by comparing valuation metrics with similar companies.
Peers
Kymera Therapeutics Related Equities
| PRLD | Prelude Therapeutics | 16.19 | ||||
| FHTX | Foghorn Therapeutics | 2.62 | ||||
| AGIO | Agios Pharm | 2.50 | ||||
| NRIX | Nurix Therapeutics | 2.40 | ||||
| STTK | Shattuck Labs | 1.83 | ||||
| CGEM | Cullinan Oncology | 1.56 | ||||
| RVMD | Revolution Medicines | 0.32 | ||||
| EWTX | Edgewise Therapeutics | 1.72 | ||||
| GLUE | Monte Rosa | 1.74 | ||||
| CCCC | C4 Therapeutics | 2.28 | ||||
| MLYS | Mineralys Therapeutics, | 2.74 | ||||
| IPSC | Century Therapeutics | 3.19 |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.